All lectures are on Tuesdays from 12 to 1 p.m. in Comer Commons at Moores Cancer Center (directions and map). Lunch is available at 11:45 a.m. for those attending the lecture.
Principles of Cancer Drug Therapeutics Development
This is a required series of 12 weekly lectures delivered by CT2 and UC San Diego faculty members during fall quarter. They focus on the necessary sequential steps in drug development.
Topics in Cancer Drug Development
This is a series of 10 monthly lectures by industry leaders in cancer drug development. The goal is to expose trainees to experts with a substantial track record in the “real life” challenges of cancer drug development. The lecturers are typically CEOs, directors of research, or medical directors from companies in the San Diego biomedical community, although experts from large pharmaceutical companies have also participated. The outside speakers are invited to discuss challenges of developing a given target or novel therapeutic and give fellows an opportunity to hear the story of the development of specific therapeutic agents.
|9/25/18||Sue Preston||Fate Therapeutics||Regulatory Concerns in the Development of Novel Agents|
|10/2/18||Paul Yazaki, PhD||City of Hope||Antibody Engineering of Novel Molecules for Clinical Applications|
|10/9/18||Pradipta Ghosh, MD||UCSD||Redefining the *Network* in Network-Based Drug Discovery: Implications in the Development of Precision Oncotherapeutics|
|10/30/18 ||Anthony Magit, MD||
UCSD||Regulations and Adventures in Human Subjects Research|
|10/23/18||Judith Varner, PhD||UCSD||Controlling Macrophage-mediated Cancer Immune Suppression|
|11/13/18||Jennifer Riggs, PhD||Celgene||TBD|
|11/20/18||Kun-Liang Guan, PhD||UCSD||The Hippo Pathway in Cell Growth, Organ Size, and Cancer|
|12/4/18||Surinder Batra, PhD||University of Nebraska||MUC4 Mucin: Clinical, Preclinical and Mechanistic Studies for the Diagnosis and Therapy of Pancreatic Cancer|
|12/11/18||Anne Wallace, MD||UCSD||Evolution of the Sentinel Node Technique, Where Studies Have Taken Us, and the Development of Tilmanocept for Sentinel Node Imaging|
Schedules for previous years